Detects human IL-13 in direct ELISAs and Western blots. In direct ELISAs, 100% cross-reactivity with recombinant rhesus monkey IL-13 is observed, approximately 50% cross-reactivity with recombinant canine IL-13 and recombinant rat IL-13 is observed, and approxmiately 15% cross‑reactivity with recombinant mouse IL-13 and recombinant cotton rat IL-13 is observed.
Polyclonal Goat IgG
E. coli-derived recombinant human IL-13 Gly21-Asn132 Accession # AAK53823
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
<0.10 EU per 1 μg of the antibody by the LAL method.
Human IL-13 transfected NS0 cells fixed with paraformaldehyde and permeabilized with saponin
Measured by its ability to neutralize IL‑13-induced proliferation in the TF‑1 human erythroleukemic cell line. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The Neutralization Dose (ND50) is typically 0.5-3 µg/mL in the presence of 10 ng/mL Recombinant Human IL‑13.
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Cell Proliferation Induced by IL‑13 and Neutralization by Human IL‑13 Antibody. Recombinant Human IL‑13 (Catalog # 213-ILB) stimulates proliferation in the TF‑1 human erythroleukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human IL‑13 (10 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL‑13 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-213-NA). The ND50 is typically 0.5-3 µg/mL.
Preparation and Storage
Reconstitute at 0.2 mg/mL in sterile PBS.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
IL-13 is a 17 kDa immunoregulatory cytokine that plays a key role in the pathogenesis of allergic asthma and atopy. It is secreted by Th1 and Th2 CD4+ T cells, NK cells, visceral smooth muscle cells, eosinophils, mast cells, and basophils (1-3). IL-13 circulates as a monomer with two internal disulfide bonds that contribute to a bundled four alpha -helix configuration (4, 5). Mature human IL-13 shares 57%, 59%, and 94% amino acid sequence identity with mouse, rat, and rhesus macaque IL-13, respectively. Despite the low homology, it exhibits cross-species activity between human, mouse, and rat (6, 7). IL-13 has diverse activities on numerous cell types (8). On macrophages, IL-13 suppresses the production of pro-inflammatory cytokines and other cytotoxic substances. On B cells, IL-13 induces immunoglobulin class switching to IgE, upregulates the expression of MHC class II, CD71, CD72, and CD23, and costimulates proliferation. IL-13 upregulates IL-6 while downregulating IL-1 and TNF-alpha production by fibroblasts and endothelial cells. IL-13 binds with low affinity to IL-13 R alpha 1, triggering IL-13 R alpha 1 association with IL-4 R alpha. This high affinity receptor complex also functions as the type 2 IL-4 receptor complex (9, 10). Additionally, IL-13 binds with high affinity to IL-13 R alpha 2 which is expressed intracellularly, on the cell surface, and as a soluble molecule (11-14). IL-13 R alpha 2 regulates the bioavailability of both IL-13 and IL-4 and is over-expressed in glioma and several bronchial pathologies (10, 15, 16). Compared to wild type IL-13, the atopy-associated R110Q variant of IL-13 elicits increased responsiveness from eosinophils that express low levels of IL-13 R alpha 2 (17).
Wills-Karp, M. (2004) Immunol. Rev. 202:175.
Nakajima H. and K. Takatsu (2007) Int. Arch. Allergy Immunol. 142:265.
McKenzie, A.N. et al. (1993) Proc. Natl. Acad. Sci. USA 90:3735.
Moy, F.J. et al. (2001) J. Mol. Biol. 310:219.
Eisenmesser, E.Z. et al. (2001) J. Mol. Biol. 310:231.
Ruetten, H. and C. Thiemermann (1997) Shock 8:409.
Lakkis, F.G. et al. (1997) Biochem. Biophys. Res. Commun. 235:529.
Wynn, T.A. (2003) Annu. Rev. Immunol. 21:425.
Andrews, A.L. et al. (2002) J. Biol. Chem. 277:46073.
Tabata, Y. et al. (2007) Curr. Allergy Asthma Rep. 7:338.
Chiaramonte, M.G. et al. (2003) J. Exp. Med. 197:687.
Daines, M.O. and G.K. Hershey (2002) J. Biol. Chem. 227:10387.
Matsumura, M. et al. (2007) Biochem. Biophys. Res. Commun. 360:464.
Tabata, Y. et al. (2007) J. Immunol. 177:7905.
Andrews, A.L. et al. (2006) J. Allergy Clin. Immunol. 118:858.
Joshi, B.H. et al. (2006) Vitam. Horm. 74:479.
Andrews, A-L. et al. (2007) J. Allergy Clin. Immunol. 120:91.
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.